The identification of the C2 subtype, characterized by TP53 mutations, elevated genomic instability, and sensitivity to PARP inhibitors, aligns with emerging evidence that metabolic reprogramming creates context-specific dependencies in cancer. The gene discussed is TP53; the disease is cancer.